Dr. Néstor A. Molfino, MD, MSc, FCCP, is a Respiratory Medicine Specialist who is now an independent clinical development consultant. Dr. Molfino works with biopharmaceutical companies, CROs, investors and patient organizations in the planning and design of their drug development strategies and respective execution either locally or globally.
Between May 2012 and January 2015 Dr. Molfino was the Chief Medical Officer at KaloBios, a public company based in South San Francisco, California, where he was developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases.
Dr. Molfino was previously Vice President, Clinical Development and Respiratory Therapeutic Area Head at MedImmune, Inc. (AstraZeneca Biologics).
He started his career in the biopharmaceutical industry in 1994. Prior to joining MedImmune, he was senior director, clinical development at Otsuka Maryland Research Institute for four years. For the past 14 years, Dr. Molfino has also served as a pulmonary and allergy consultant to Fermin Salaberry, a non-profit public community hospital in Argentina.
Dr. Molfino received a Master’s degree in Molecular and Cell Biology from the University of Toronto. He holds a Medical degree from Universidad Nacional de Rosario in Argentina, completing an internship and residency in internal medicine and respiratory medicine after which he went to Toronto, Canada for a post-doctoral fellowship at the University of Toronto where he was appointed assistant professor in 2004. In 2006, he was also appointed Adjunct Professor at McGill University in Montreal, Canada.
Website last updated August, 2016